HNSBF News and Press, Hansa Biopharma AB From 02/04/23

Hansa Biopharma AB (publ) (HNSBF) Q4 2022 Earnings Conference Call February 02, 2023, 08:00 AM ET Company Participants Søren Tulstrup - President and CEO Donato Spota - SVP and CFO Conference Call Participants Gonzalo Attali - ABG Sundal Collier Zoe Ka...

The following slide deck was published by Hansa Biopharma AB (publ) in conjunction with their 2022 Q4 earnings call. For further details see: Hansa Biopharma AB (publ) 2022 Q4 - Results - Earnings Call Presentation

Hansa Biopharma press release ( OTCPK:HNSBF ): Q4 GAAP EPS of -SEK 3.19. Revenue of SEK 31M (+101.3% Y/Y). Cash runway extended into 2025. For further details see: Hansa Biopharma GAAP EPS of -SEK 3.19, revenue of SEK 31M

Hansa Biopharma AB (HNSBF) Q3 2022 Earnings Conference Call October 20, 2022 8:00 AM ET Company Participants Soren Tulstrup - President and Chief Executive Officer Donato Spota - Senior Vice President, Chief Financial Officer Conference Call Participants ...

The following slide deck was published by Hansa Biopharma AB (publ) in conjunction with their 2022 Q3 earnings call. For further details see: Hansa Biopharma AB (publ) 2022 Q3 - Results - Earnings Call Presentation

Hansa Biopharma press release ( OTCPK:HNSBF ): Q3 GAAP EPS of -SEK 3.45. Revenue of SEK 67M (+1253.5% Y/Y). For further details see: Hansa Biopharma GAAP EPS of -SEK 3.45, revenue of SEK 67M

The Scottish Medicines Consortium (SMC) recommends use of Hansa Biopharma's Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients PR Newswire Idefirix ® becomes the first and only product recommended by SMC...

Hansa Biopharma AB (publ) (HNSBF) Q2 2022 Earnings Conference Call July 19, 2022 08:00 AM ET Company Participants Søren Tulstrup - CEO Donato Spota - CFO Conference Call Participants Dominic Rose - Intron Health Research Douglas Tsao - H.C. Wainw...

The following slide deck was published by Hansa Biopharma AB (publ) in conjunction with their 2022 Q2 earnings call. For further details see: Hansa Biopharma AB (publ) 2022 Q2 - Results - Earnings Call Presentation

press release ( OTCPK:HNSBF ): 1H GAAP EPS of -SEK6.94. Revenue of SEK56.7M (+320.0% Y/Y). For further details see: GAAP EPS of -SEK6.94, revenue of SEK56.7M